Search

This article discusses the treatment options for patients with geographic atrophy (GA), a condition that can lead to vision loss. Retina specialists emphasize the importance of early diagnosis and treatment to slow the progression of GA. Two intravitreal drugs, pegcetacoplan and avacincaptad pegol, have shown promise in slowing GA growth by up to 20% over 12 to 24 months. Treatment frequency can vary, but every 6 to 8 weeks is generally recommended. It is important for patients to be well-informed about the benefits and risks of these therapies. [Extracted from the article]

The article discusses new advancements in managing retinal diseases, highlighting treatments like Vabysmo and Eylea High Definition (HD) that reduce injection frequency for wet Age-related Macular Degeneration (AMD), and complement inhibitor drugs for delaying geographic atrophy progression. It highlights the importance of early referral to retina specialists, effective treatment strategies, and the role of optometrists in maintaining patients' visual health through collaborative care.

The article discusses the efforts that can position optometry for great advancement and approved demand for socialization to manifest. Topics include patients who have been putting off routine care will return; and long-term consequences of SARS-Cov-2—potentially impairing the heart, and lungs are unfortunately significant.

The article discusses a multicenter phase I trial, which investigates a complement inhibitor, POT-4, in patients with active age-related macular degeneration (AMD). Researcher Jason S. Slakter informs that the drug is being developed as a locally administered compound with the aim to treat patients with early disease and reduce the risk of progression leading to vision loss. It is observed that there is a scientific basis for developing complement inhibition as a therapeutic strategy.

The article presents a study which evaluates the effectiveness of POT-4, a complement inhibitor from Potentia Pharmaceuticals Inc. Result of the phase I in vivo clinical trial shows that there is no significant adverse ocular or systematic side effects when it is administered up to 450 microgram in every eye. It concludes that POT-4 will shot down the complement activation that can prevent tissue damage, inflammation and upregulation of vascular endothelial growth factor (VEGF).